https://scholars.lib.ntu.edu.tw/handle/123456789/545289
標題: | Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: A review of the literature | 作者: | Chen D.-Y. Lau C.S. Elzorkany B. PING-NING HSU Praprotnik S. Vasilescu R. Marshall L. Llamado L. |
關鍵字: | Biologic; Discontinuation; Down-titration; Rheumatoid arthritis | 公開日期: | 2018 | 出版社: | Blackwell Publishing | 卷: | 21 | 期: | 2 | 起(迄)頁: | 362-372 | 來源出版物: | International Journal of Rheumatic Diseases | 摘要: | Aim: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. Methods: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if one or more of the following biologic disease modifying antirheumatic drugs (bDMARDs) was evaluated: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab. Results: Five studies qualified for inclusion. The populations of patients with RA were heterogeneous among the studies; patients were required to have low disease activity (LDA) or to be in remission prior to dose titration. Approximately 25–65% of patients successfully decreased and in some cases, discontinued the bDMARD. However, the flare rate was higher than for the patients who remained on a standard dose. The only variable that predicted relapse in more than one study was down-titration of the bDMARD dose. Conclusion: In patients who have achieved LDA or remission, down-titration and discontinuation of bDMARD therapy may be attempted, with careful monitoring. However, it is likely that some patients will flare, and it is not known how to predict these patients. ? 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038237496&doi=10.1111%2f1756-185X.13238&partnerID=40&md5=64b2ce3cd4814efbb40d702b9528c624 https://scholars.lib.ntu.edu.tw/handle/123456789/545289 |
ISSN: | 1756-1841 | DOI: | 10.1111/1756-185X.13238 | SDG/關鍵字: | abatacept; adalimumab; certolizumab pegol; etanercept; golimumab; infliximab; interleukin 1 receptor blocking agent; interleukin 6 receptor; rituximab; tocilizumab; tumor necrosis factor inhibitor; antirheumatic agent; biological product; biological therapy; clinical outcome; disease activity; disease duration; drug dose titration; drug monitoring; drug screening; drug withdrawal; human; prediction; priority journal; remission; Review; rheumatoid arthritis; T lymphocyte activation; treatment withdrawal; cost benefit analysis; drug administration; drug cost; economics; immunology; recurrent disease; rheumatoid arthritis; time factor; treatment outcome; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Humans; Recurrence; Remission Induction; Time Factors; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。